A Phase 2/3 interventional study of IFX-1 + BSC and BSC in Severe COVID-19 Pneumonia, sponsored by InflaRx GmbH. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by InflaRx GmbH · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.
Among the 782 studies in COVID-19 with a site in France, this one is the 81st largest by enrollment of the 294 interventional ones that give a count, is one of 499 that started in 2020, is one of 14 in phase 2/3, and was the 28th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Hospices Civils de Lyon · Sites in France
Ages 8–18
Laboratoire de la Mer · Sites in France
Ages 15 days+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
782 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 57 · Phase 3 64 · Phase 4 4
First in 2016; this study’s year is marked. 499 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 399 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 130 across the 294 interventional studies, 298 across the 486 observational. Of the 530 that completed or were terminated, 39 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 782 have an industry lead sponsor. The 10 most frequent:
InflaRx GmbH is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
InflaRx GmbH has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 782 studies in COVID-19 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II \& Phase III:
This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled, randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC + placebo-to-match (Arm B)
The phase II and Phase III portions enrolled patients subsequently.
1st patient was enrolled in the phase III portion on 1st October 2020.
Phase II
Inclusion Criteria:
Exclusion Criteria:
Phase III:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase II study part: IFX-1: 800mg intravenously administered, BSC: Best supportive care
Drug: IFX-1 + BSC
Phase II study part: BSC: Best supportive care
Drug: BSC
Phase III study part: IFX-1: 800mg intravenously administered, SOC: Standard of care
Drug: IFX-1 + SOC
Phase III study part: Placebo: placebo infusion intravenously administered, SOC: Standard of care
Drug: Placebo + SOC
Phase II study part: IFX-1 + BSC
Also known as: Vilobelimab + Best Supportive Care
Phase II study part: BSC
Also known as: Best Supportive Care
Drug page: Vilobelimab
Phase III study part: IFX-1 + SOC
Also known as: Vilobelimab + Standard of Care
Phase III study part: Placebo + SOC
Also known as: Placebo + Standard of Care
Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS)
Relative change (%) from baseline in Oxygenation Index (OI; partial pressure of oxygen in the arterial blood (PaO2) / fractional inspired oxygen (FiO2)) in supine position for ≥2 hours at day 5 (FAS)
Time frame: Baseline and Day 5
Phase III: 28-day All-cause Mortality (FAS)
Number and percentage of deaths (all-cause) until Day 28 (FAS)
Time frame: Day 28
Phase II: All-cause 28-day Mortality (FAS)
Number and percentage of deaths (all-cause) until Day 28 (FAS)
Time frame: Day 28
Phase II: Early Response at Day 7 After Enrollment
Number of patients (%) achieving an early response at day 7 after enrollment (FAS)
Time frame: Day 7
Phase II: Late Response Until Day 28 After Enrollment
Number of patients (%) reaching a late response until day 28 (FAS)
Time frame: Baseline until Day 28
Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position (FAS)
Relative change (%) from baseline in Oxygenation Index (OI) in supine position for ≥2 hours at days 3, 7, 9, 11, and 15 (FAS)
Time frame: Baseline, Day 3, Day 7, Day 9, Day 11, Day 15
Phase III: 60-day All-cause Mortality (FAS)
Number and percentage of deaths (all-cause) until Day 60 (FAS)
Time frame: Day 60
Phase III: Percentage of Patients With an Improvement in the 8-point Ordinal Scale (FAS)
Percentage of patients with an improvement in the 8-point ordinal scale (Day 15, Day 28), the scale ranges from 0 = 'No clinical or virological evidence of infection' to 8 = 'Death' with higher scores meaning greater limitation and ventilation/organ support
Time frame: Day 15, Day 28
Phase III: Percentage of Patients Developing Acute Kidney Failure Until Day 28 (FAS)
Percentage of patients developing acute kidney failure (estimated glomerular filtration rate \[eGFR\] \< 15 mL/min/1.73m², assessed by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation requiring race information) until Day 28 (FAS)
Time frame: Day 28
Phase III: Percentage of Patients Free of Any Renal Replacement Therapy Within 28 Days Upon Randomization (FAS)
Percentage of patients free of any renal replacement therapy (RRT) within 28 days upon randomization (FAS), number of patients free of any RRT = number of patients - number of patients with RRT initiated after randomization until Day 28
Time frame: Day 28
| Milestone | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|---|---|
| Started | 15 | 15 | 178 | 191 |
| Contributed to full analysis set (fas) | 15 | 15 | 177 | 191 |
| Contributed to safety analysis set (saf) | 15 | 15 | 175 | 189 |
| Completed | 13 | 11 | 103 | 93 |
| Not completed | 2 | 4 | 75 | 98 |
Relative change (%) from baseline in Oxygenation Index (OI; partial pressure of oxygen in the arterial blood (PaO2) / fractional inspired oxygen (FiO2)) in supine position for ≥2 hours at day 5 (FAS)
| percentage of change | Phase II: IFX-1 + BSC | Phase II: BSC |
|---|---|---|
| Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS) | 15.5 (-11.4 to 42.4) | 31.9 (6.0 to 57.9) |
Number and percentage of deaths (all-cause) until Day 28 (FAS)
| Participants | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|
| Dead | 54 | 77 |
| Alive | 115 | 105 |
| Missing | 8 | 9 |
Number and percentage of deaths (all-cause) until Day 28 (FAS)
| Participants | Phase II: IFX-1 + BSC | Phase II: BSC |
|---|---|---|
| Phase II: All-cause 28-day Mortality (FAS) | 2 | 4 |
Number of patients (%) achieving an early response at day 7 after enrollment (FAS)
No measurements were reported for this outcome.
Number of patients (%) reaching a late response until day 28 (FAS)
No measurements were reported for this outcome.
Relative change (%) from baseline in Oxygenation Index (OI) in supine position for ≥2 hours at days 3, 7, 9, 11, and 15 (FAS)
| percentage of change | Phase II: IFX-1 + BSC | Phase II: BSC |
|---|---|---|
| Day 3 | 7.1 (-10.3 to 24.4) | 17.6 (0.8 to 34.4) |
| Day 7 | 13.1 (-23.4 to 49.6) | 36.0 (0.8 to 71.2) |
| Day 9 | 20.7 (-15.5 to 56.9) | 27.8 (-7.2 to 62.8) |
| Day 11 | 45.5 (2.1 to 88.9) | 43.5 (1.7 to 85.4) |
| Day 15 | 78.5 (19.1 to 138.0) | 82.6 (25.2 to 140.0) |
Number and percentage of deaths (all-cause) until Day 60 (FAS)
| Participants | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|
| Dead | 62 | 87 |
| Alive | 102 | 93 |
| Missing | 13 | 11 |
Percentage of patients with an improvement in the 8-point ordinal scale (Day 15, Day 28), the scale ranges from 0 = 'No clinical or virological evidence of infection' to 8 = 'Death' with higher scores meaning greater limitation and ventilation/organ support
| Participants | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|
| Improved | 82 | 77 |
| Not improved | 86 | 104 |
| Not evaluable | 9 | 10 |
Percentage of patients developing acute kidney failure (estimated glomerular filtration rate \[eGFR\] \< 15 mL/min/1.73m², assessed by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation requiring race information) until Day 28 (FAS)
| Participants | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|
| Acute kidney failure | 8 | 12 |
| No acute kidney failure | 158 | 168 |
| Not evaluable | 11 | 11 |
Percentage of patients free of any renal replacement therapy (RRT) within 28 days upon randomization (FAS), number of patients free of any RRT = number of patients - number of patients with RRT initiated after randomization until Day 28
| Participants | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC |
|---|---|---|
| Phase III: Percentage of Patients Free of Any Renal Replacement Therapy Within 28 Days Upon Randomization (FAS) | 160 | 161 |
Collected over Phase II study part: 4 weeks; Phase III study part: 60 days;. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase II: IFX-1 + BSC | 2/15 (13.3%) | 9/15 (60%) | 14/15 (93.3%) |
| Phase II: BSC | 4/15 (26.7%) | 7/15 (46.7%) | 14/15 (93.3%) |
| Phase III: IFX-1 + SOC | 62/175 (35.4%) | 103/175 (58.9%) | 147/175 (84%) |
| Phase III: Placebo + SOC | 86/189 (45.5%) | 122/189 (64.6%) | 154/189 (81.5%) |
| Phase III: Randomized Non-treated Patients | 1/5 (20%) | 2/5 (40%) | 0/5 (0%) |
| Event | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Phase III: Randomized Non-treated Patients |
|---|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/15 | 6/15 | 12/175 | 14/189 | 0/5 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/15 | 4/15 | 16/175 | 21/189 | 0/5 |
| PneumoniaInfections and infestations | 1/15 | 3/15 | 21/175 | 16/189 | 0/5 |
| Cardiac failure acuteCardiac disorders | 0/15 | 0/15 | 1/175 | 0/189 | 1/5 |
| Hypertensive emergencyVascular disorders | 0/15 | 0/15 | 0/175 | 0/189 | 1/5 |
| Acute kidney injuryRenal and urinary disorders | 0/15 | 1/15 | 16/175 | 31/189 | 0/5 |
| Septic shockInfections and infestations | 0/15 | 0/15 | 24/175 | 30/189 | 0/5 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/15 | 1/15 | 20/175 | 24/189 | 0/5 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/15 | 0/15 | 5/175 | 3/189 | 0/5 |
| DeliriumPsychiatric disorders | 2/15 | 0/15 | 0/175 | 0/189 | 0/5 |
| Event | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Phase III: Randomized Non-treated Patients |
|---|---|---|---|---|---|
| Impaired gastric emptyingGastrointestinal disorders | 4/15 | 7/15 | 4/175 | 3/189 | 0/5 |
| Decubitus ulcerSkin and subcutaneous tissue disorders | 4/15 | 6/15 | 4/175 | 5/189 | 0/5 |
| HypernatraemiaMetabolism and nutrition disorders | 4/15 | 5/15 | 11/175 | 13/189 | 0/5 |
| HypophosphataemiaMetabolism and nutrition disorders | 4/15 | 5/15 | 2/175 | 8/189 | 0/5 |
| HypokalaemiaMetabolism and nutrition disorders | 4/15 | 4/15 | 7/175 | 8/189 | 0/5 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/15 | 3/15 | 6/175 | 11/189 | 0/5 |
| DeliriumPsychiatric disorders | 3/15 | 4/15 | 14/175 | 13/189 | 0/5 |
| Oedema peripheralGeneral disorders | 0/15 | 4/15 | 10/175 | 9/189 | 0/5 |
| ConstipationGastrointestinal disorders | 2/15 | 4/15 | 6/175 | 3/189 | 0/5 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/15 | 1/15 | 10/175 | 6/189 | 0/5 |
Full Analysis Set (excluding one subject who was randomized in error to group Phase III: IFX-1 + SOC)
| Age, Continuous(years) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| Mean | 57.5 ± 8.6 | 62.8 ± 8.1 | 56.7 ± 13.2 | 55.9 ± 14.5 | 56.6 ± 13.6 |
| Sex: Female, Male(Participants) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | 52 | 64 | 124 |
| Male | 11 | 11 | 125 | 127 | 274 |
| Race/Ethnicity, Customized(Participants) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| Race — White | 8 | 11 | 115 | 119 | 253 |
| Race — Asian | 5 | 2 | 4 | 5 | 16 |
| Race — Black or African American | 2 | 2 | 5 | 8 | 17 |
| Race — American Indian or Alaskan Native | 0 | 0 | 22 | 24 | 46 |
| Race — Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Race — Multiple | 0 | 0 | 1 | 0 | 1 |
| Race — Other | 0 | 0 | 16 | 19 | 35 |
| Race — Not reported | 0 | 0 | 14 | 16 | 30 |
| Race/Ethnicity, Customized(Participants) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 60 | 68 | 128 |
| Ethnicity — Not Hispanic or Latino | 15 | 15 | 70 | 73 | 173 |
| Ethnicity — Not Reported | 0 | 0 | 28 | 35 | 63 |
| Ethnicity — Unknown | 0 | 0 | 11 | 11 | 22 |
| Ethnicity — Missing | 0 | 0 | 8 | 4 | 12 |
| Intubation status(Participants) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| No | 7 | 5 | 0 | 0 | 12 |
| Yes | 8 | 10 | 177 | 191 | 386 |
| Oxygenation index(index) | Phase II: IFX-1 + BSC | Phase II: BSC | Phase III: IFX-1 + SOC | Phase III: Placebo + SOC | Total |
|---|---|---|---|---|---|
| Mean | 137.9 ± 51.1 | 144.2 ± 41.5 | 131.9 ± 39.2 | 130.6 ± 44.8 | 131.9 ± 42.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Oct 2021, 19 months.
Results were first posted in Jun 2023, 1 year 7 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 19 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilobelimab
InflaRx GmbH